Quarterly report pursuant to Section 13 or 15(d)

Reverse Recapitalization - Consummation of the merger (Details)

v3.21.2
Reverse Recapitalization - Consummation of the merger (Details) - shares
3 Months Ended 9 Months Ended
May 24, 2021
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Business Acquisition [Line Items]        
Merger and PIPE Financing shares - common stock   511,065    
Total shares of common stock immediately after Merger   0 0 42,973,462
Merger agreement        
Business Acquisition [Line Items]        
Common stock, outstanding prior to Merger   552,412 552,412  
Less: redemption of BRPA shares     (216)  
Common stock of BRPA   552,196 552,196  
Shares issued in PIPE Financing     1,000,000  
Shares issued for services     200,000  
Shares issued pursuant to conversion of Public and Private Rights     717,250  
Merger and PIPE Financing shares - common stock     3,729,730  
Total shares of common stock immediately after Merger   48,603,585 48,603,585  
Merger agreement | Stockholders of NeuroRx        
Business Acquisition [Line Items]        
BRPA Founder and private shares, net of forfeited shares of 875,216 50,000,000      
NeuroRx shares - common stock (1)     44,873,855  
Common stock outstanding upon conversion prior to Merger   14,200,586 14,200,586  
Merger agreement | BRPA Founder and private shares        
Business Acquisition [Line Items]        
BRPA Founder and private shares, net of forfeited shares of 875,216     1,260,284  
Number of shares forfeited     875,216